Drug Database · Clinicians

Tipiracil + Trifluridine

Brands (1) LonsurfShow all

Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor (Nucleic Acid Synthesis Inhibitors) US FDA class
Antineoplastic agents PH FDA category
Fixed-dose combination.

Rx · Prescription drug2 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f5beed22-d71d-4c0d-8dca-2c7317d65d85, version date November 5, 2025 (LONSURF · Taiho Pharmaceutical Co., Ltd.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy…
  • metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

(1.2) 1.1 Metastatic Colorectal Cancer LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. 1.2 Metastatic Gastric Cancer LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Contraindications

4 CONTRAINDICATIONS None. None. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Recommended Dosage: 35 mg/m 2 /dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1)

2.1 Recommended Dosage

2.1 Recommended Dosage The recommended dosage of LONSURF as a single agent or in combination with bevacizumab is 35 mg/m 2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment.

Refer to the Prescribing Information for bevacizumab dosing information. Instruct patients to swallow LONSURF tablets whole. Instruct patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose. LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Table 1 shows the calculated initial daily dose based on body surface area (BSA).

Table 1: Recommended Dosage According to Body Surface Area (BSA) BSA (m2) Total daily dose (mg) Dose (mg) administered twice daily Tablets per dose 15 mg 20 mg < 1.07 70 35 1 1 1.07 – 1.22 80 40 0 2 1.23 – 1.37 90 45 3 0 1.38 – 1.52 100 50 2 1 1.53 – 1.68 110 55 1 2 1.69 – 1.83 120 60 0 3 1.84 – 1.98 130 65 3 1 1.99 – 2.14 140 70 2 2 2.15 – 2.29 150 75 1 3 ≥2.30 160 80 0 4

2.2 Dosage Modifications for Adverse Reactions

2.2 Dosage Modifications for Adverse Reactions Obtain complete blood cell counts prior to and on Day 15 of each cycle [see Warnings and Precautions (5.1)]. Do not initiate the cycle of LONSURF until: Absolute neutrophil count (ANC) greater than or equal to 1,500/mm 3 or febrile neutropenia is resolved Platelets greater than or equal to 75,000/mm 3 Grade 3 or 4 non-hematological adverse reactions are resolved to Grade 0 or 1 Within a treatment cycle, withhold LONSURF for any of the following: Absolute neutrophil count (ANC) less than 500/mm 3 or febrile neutropenia Platelets less than 50,000/mm 3 Grade 3 or 4 non-hematologic adverse reaction After recovery, resume LONSURF after reducing the dose by 5 mg/m 2 /dose from the previous dose, if the following occur: Febrile neutropenia Uncomplicated Grade 4 neutropenia (which has recovered to greater than or equal to 1,500/mm 3) or thrombocytopenia (which has recovered to greater than or equal to 75,000/mm 3) that results in more than 1 week delay in start of next cycle Non-hematologic Grade 3 or Grade 4 adverse reaction except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or Grade 3 diarrhea responsive to antidiarrheal medication A maximum of 3 dose reductions are permitted.

Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 20 mg/m 2 orally twice daily. Do not escalate LONSURF dosage after it has been reduced. Refer to the bevacizumab prescribing information for dose modifications for adverse reactions associated with bevacizumab.

2.3 Recommended Dosage for Renal Impairment Severe Renal

2.3 Recommended Dosage for Renal Impairment Severe Renal Impairment In patients with severe renal impairment [creatinine clearance (CLcr) of 15 to 29 mL/min as determined by the Cockcroft-Gault formula], the recommended dosage is 20 mg/m 2 (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle (Table 2) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Reduce dose to 15 mg/m 2 twice daily in patients with severe renal impairment who are unable to tolerate a dose of 20 mg/m 2 twice daily (Table 2).

Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 15 mg/m 2 twice daily. Table 2: Recommended Dosage for Severe Renal Impairment According to BSA BSA (m 2) Total daily dose (mg) Dose (mg) administered twice daily Tablets per dose 15 mg 20 mg For a dose of 20 mg/m 2 twice daily: < 1.14 40 20 0 1 1.14 – 1.34 50 25 For a total daily dose of 50 mg, instruct patients to take 1 x 20-mg tablet in the morning and 2 x 15-mg tablets in the evening. 2 in the evening 1 in the morning 1.35 – 1.59 60 30 2 0 1.60 – 1.94 70 35 1 1 1.95 – 2.09 80 40 0 2 2.10 – 2.34 90 45 3 0 ≥ 2.35 100 50 2 1 For a dose of 15 mg/m 2 twice daily: < 1.15 30 15 1 0 1.15 – 1.49 40 20 0 1 1.50 – 1.84 50 25 2 in the evening 1 in the morning 1.85 – 2.09 60 30 2 0 2.10 – 2.34 70 35 1 1 ≥ 2.35 80 40 0 2

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations, pharmacokinetics)

2.3 Recommended Dosage for Renal Impairment Severe Renal Impairment In patients with severe renal impairment [creatinine clearance (CLcr) of 15 to 29 mL/min as determined by the Cockcroft-Gault formula], the recommended dosage is 20 mg/m 2 (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle (Table 2) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Reduce dose to 15 mg/m 2 twice daily in patients with severe renal impairment who are unable to tolerate a dose of 20 mg/m 2 twice daily (Table 2).

Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 15 mg/m 2 twice daily. Table 2: Recommended Dosage for Severe Renal Impairment According to BSA BSA (m 2) Total daily dose (mg) Dose (mg) administered twice daily Tablets per dose 15 mg 20 mg For a dose of 20 mg/m 2 twice daily: < 1.14 40 20 0 1 1.14 – 1.34 50 25 For a total daily dose of 50 mg, instruct patients to take 1 x 20-mg tablet in the morning and 2 x 15-mg tablets in the evening. 2 in the evening 1 in the morning 1.35 – 1.59 60 30 2 0 1.60 – 1.94 70 35 1 1 1.95 – 2.09 80 40 0 2 2.10 – 2.34 90 45 3 0 ≥ 2.35 100 50 2 1 For a dose of 15 mg/m 2 twice daily: < 1.15 30 15 1 0 1.15 – 1.49 40 20 0 1 1.50 – 1.84 50 25 2 in the evening 1 in the morning 1.85 – 2.09 60 30 2 0 2.10 – 2.34 70 35 1 1 ≥ 2.35 80 40 0 2

8.6 Renal Impairment No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr of 30 to 89 mL/min as determined by the Cockcroft-Gault formula). Reduce the dose of LONSURF for patients with severe renal impairment (CLcr of 15 to 29 mL/min) [see Dosage and Administration (2.3)]. The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with end stage renal disease.

Patients with Renal Impairment In a dedicated renal impairment study, all patients received LONSURF 35 mg/m 2 twice daily except for patients with severe renal impairment who received 20 mg/m 2 twice daily. Mild renal impairment (CLcr of 60 to 89 mL/min as determined by the Cockcroft-Gault formula) had no clinically important effect on steady-state AUC 0-last of trifluridine and tipiracil.

Moderate renal impairment (CLcr of 30 to 59 mL/min) increased steady-state AUC 0-last of trifluridine by 56% and tipiracil by 139% compared to normal renal function (CLcr ≥ 90 mL/min). Severe renal impairment (CLcr of 15 to 29 mL/min) increased the dose-normalized steady-state AUC 0-last of trifluridine by 140% and tipiracil by 614% compared to normal renal function.

The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with end stage renal disease.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment No adjustment to the starting dosage of LONSURF is recommended for patients with mild hepatic impairment. Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin >1.5 times ULN and any AST) hepatic impairment [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of LONSURF in pediatric patients have not been established. Juvenile Animal Toxicity Data Dental toxicity including whitening, breakage, and malocclusion (degeneration and disarrangement in the ameloblasts, papillary layer cells and odontoblasts) were observed in rats treated with trifluridine/tipiracil at doses ≥ 50 mg/kg (approximately 0.33 times the exposure at the clinical dose of 35 mg/m 2 twice daily).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 1114 patients with metastatic colorectal cancer or gastric cancer who received single agent LONSURF in clinical studies, 45% were 65 years of age or over, and 11% were 75 and over. In the 246 patients who received LONSURF in combination with bevacizumab; 41% were 65 years of age or over, and 10% were 75 and over.

While these studies were not designed to detect a difference in efficacy, no overall differences were observed in patients 65 or older versus younger patients with either LONSURF as a single agent or LONSURF in combination with bevacizumab. Patients 65 years of age or older who received LONSURF as a single agent had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs 32%), Grade 3 anemia (20% vs 14%), and Grade 3 or 4 thrombocytopenia (6% vs 3%).

Patients 65 years of age or older who received LONSURF in combination with bevacizumab had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (60% vs 46%) and Grade 3 or 4 thrombocytopenia (5% vs 4%).

Dosage forms

Philippines

  • Film-coated tablet: 15 mg/6.14 mg, 20 mg/8.19 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Tipiracil + Trifluridine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Tipiracil + Trifluridine
Package insert
LonsurfTrifluridine + Tipiracil (as Hydrochloride)
15 mg/6.14 mg Film-Coated TabletAlu-PP Blister Pack x 10's in Alu Foil Pouch (Box of 20's)
Rx
Taiho Pharmaceutical Co., Ltd. (Kitajima Plant)Japan
Globo Asiatico Enterprises, Inc.Importer: Taiho Pharma Asia Pacific Pte. Ltd. Philippine Branch
DR-XY48411
Oct 7, 2027
LonsurfTrifluridine + Tipiracil (as Hydrochloride)
20 mg/8.19 mg Film-Coated TabletAlu-PP Blister Pack x 10's in Alu Foil Pouch (Box of 20's)
Rx
Taiho Pharmaceutical Co., Ltd. (Kitajima Plant)Japan
Globo Asiatico Enterprises, Inc.Importer: Taiho Pharma Asia Pacific Pte. Ltd. Philippine Branch
DR-XY48410
Oct 7, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Tablets: 15 mg trifluridine/6.14 mg tipiracil: white, biconvex, round, film-coated, imprinted with ‘15’ on one side, and ‘102’ and ‘15 mg’ on the other side, in gray ink. 20 mg trifluridine/8.19 mg tipiracil: pale red, biconvex, round, film-coated, imprinted with ‘20’ on one side, and ‘102’ and ‘20 mg’ on the other side, in gray ink. Tablets: 15 mg trifluridine/6.14 mg tipiracil (3) 20 mg trifluridine/8.19 mg tipiracil (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1)
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.2, 8.1, 8.3)
5.1 Severe Myelosuppression

5.1 Severe Myelosuppression In the 1114 patients who received LONSURF as a single agent, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (38%), anemia (17%), thrombocytopenia (4%) and febrile neutropenia (3%). Three patients (0.3%) died due to neutropenic infection/sepsis; four other patients (0.5%) died due to septic shock.

A total of 14% of patients received granulocyte-colony stimulating factors. In the 246 patients who received LONSURF in combination with bevacizumab, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (52%), anemia (5%), thrombocytopenia (4%) and febrile neutropenia (0.4%). One patient (0.4%) died due to abdominal sepsis and two other patients (0.8%) died due to septic shock.

A total of 29% of patients received granulocyte-colony stimulating factors. Obtain complete blood counts prior to and on Day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for severe myelosuppression and resume at the next lower dosage [see Dosage and Administration (2.2)].

5.2 Embryo-Fetal Toxicity

5.2 Embryo-Fetal Toxicity Based on animal studies and its mechanism of action, LONSURF can cause fetal harm when administered to a pregnant woman. Trifluridine/tipiracil caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when orally administered during gestation at dosage levels resulting in exposures lower than those achieved at the recommended dosage of 35 mg/m 2 twice daily.

Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with LONSURF and for at least 6 months after the final dose [see Use in Specific Populations (8.1, 8.3)].

Drug interactions

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Drug Interaction Studies In vitro studies indicated that trifluridine, tipiracil, and FTY did not inhibit the CYP enzymes and had no inductive effect on CYP1A2, CYP2B6, or CYP3A4/5.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Severe Myelosuppression [see Warnings and Precautions (5.1)] The most common adverse reactions or laboratory abnormalities for single agent LONSURF (≥10%) are neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. (6.1) The most common adverse reactions or laboratory abnormalities for LONSURF in combination with bevacizumab (≥20%) are neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased AST, increased ALT, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite.

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Taiho Oncology, Inc. at 1-844-878-2446 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in the WARNINGS AND PRECAUTIONS section and below reflect exposure to LONSURF at the recommended dose in 533 patients with metastatic colorectal cancer in RECOURSE, 246 patients with metastatic colorectal cancer treated with LONSURF as monotherapy in SUNLIGHT and 335 patients with metastatic gastric cancer in TAGS.

Among the 1114 patients who received LONSURF as a single agent, 12% were exposed for 6 months or longer and 1% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities (≥10%) were neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia.

Among the 246 patients with metastatic colorectal cancer treated with LONSURF in combination with bevacizumab in SUNLIGHT, 39% were exposed for 6 months or longer, and 14% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities (≥20%) were neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased AST, increased ALT, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite.

Metastatic Colorectal Cancer LONSURF as a single agent The safety of LONSURF was evaluated in RECOURSE, a randomized (2:1), double-blind, placebo-controlled trial in patients with previously treated metastatic colorectal cancer [see Clinical Studies (14.1)]. Patients received LONSURF 35 mg/m 2 /dose (n=533) or placebo (n=265) twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.

In RECOURSE, 12% of patients received LONSURF for more than 6 months and 1% of patients received LONSURF for more than 1 year. The study population characteristics were: median age 63 years; 61% male; 57% White, 35% Asian, and 1% Black. The most common adverse reactions or laboratory abnormalities (≥10% in incidence) in patients treated with LONSURF at a rate that exceeds the rate in patients receiving placebo were anemia, neutropenia, asthenia/fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia.

In RECOURSE, 3.6% of patients discontinued LONSURF for an adverse reaction and 14% of patients required a dose reduction. The most common adverse reactions or laboratory abnormalities leading to dose reduction were neutropenia, anemia, febrile neutropenia, fatigue, and diarrhea. Table 3 and Table 4 list the adverse reactions and laboratory abnormalities (graded using CTCAE v4.03), respectively, observed in RECOURSE.

Table 3: Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in RECOURSE Adverse Reactions LONSURF (N=533) Placebo (N=265) All Grades (%) Grades 3-4 No Grade 4 definition for nausea, abdominal pain, or fatigue in National Cancer Institute Common Terminology (%) All Grades (%) Grades 3-4 (%) General Asthenia/fatigue 52 7 35 9 Pyrexia 19 1.3 14 0.4 Gastrointestinal Nausea 48 1.9 24 1.1 Diarrhea 32 3 12 0.4 Vomiting 28 2.1 14 0.4 Abdominal pain 21 2.4 19 3.8 Stomatitis 8 0.4 6 0 Metabolism and nutrition Decreased appetite 39 3.6 29 4.9 Infections Incidence reflects 64 preferred terms in the Infections and Infestations system organ class. 27 7 16 4.9 Nervous system Dysgeusia 7 0 2.3 0 Skin and subcutaneous tissue Alopecia 7 0 1.1 0 Table 4: Select Laboratory Abnormalities in RECOURSE Laboratory Parameter Worst Grade at least one grade higher than baseline, with percentages based on number of patients with post-baseline samples, which may be <533 (LONSURF) or 265 (placebo) LONSURF Placebo All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Hematologic Anemia One Grade 4 anemia adverse reaction based on clinical criteria was reported 77 18 33 3 Neutropenia 67 38 0.8 0 Thrombocytopenia 42 5 8 0.4 In RECOURSE, pulmonary emboli occurred more frequently in LONSURF-treated patients (2%) compared to no patients on placebo. LONSURF in combination with bevacizumab The safety of LONSURF in combination with bevacizumab was evaluated in SUNLIGHT, an international, randomized, open label study in patients with previously treated metastatic colorectal cancer [see Clinical Studies (14.1)].

The study population characteristics were: median age 63 years (20 to 90 years); 52% male; 88% White, 1.4% Black, 0.2% Asian, 0.2% American Indian or Alaska Native, and 9.6% were unknown; and baseline ECOG performance status 0 (46%), 1 (54%), or 2 (0.2%). Serious adverse reactions occurred in 25% of patients. The most frequent serious adverse reactions (≥2%) were intestinal obstruction (2.8%), and COVID-19 (2%).

Fatal adverse reactions occurred in 1.2% of patients who received LONSURF in combination with bevacizumab, including rectal fistula (0.4%), bowel perforation (0.4%) and atrial fibrillation (0.4%). Permanent treatment discontinuation due to an adverse reaction occurred in 13% of patients. The adverse reaction which resulted in permanent treatment discontinuation in ≥2% of patients was fatigue.

Dosage reductions due to an adverse reaction or laboratory abnormality occurred in 7% of patients. At least one dose reduction in 3.7% of patients was required for neutropenia. Dosage interruptions due to an adverse reaction occurred in 11% of patients who received LONSURF in combination with bevacizumab. The adverse reaction that required dosage interruption in ≥2% of patients was nausea.

The most common adverse reactions or laboratory abnormalities (≥20% in incidence) in patients treated with LONSURF in combination with bevacizumab were neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased aspartate aminotransferase, increased alanine aminotransferase, increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite. Table 5 and Table 6 list the adverse reactions and laboratory abnormalities, respectively, observed in SUNLIGHT.

Table 5: Adverse Reactions (≥5%) in SUNLIGHT Adverse Reactions LONSURF + Bevacizumab (N=246) (%) LONSURF (N=246) (%) All Grades Grade 3 or 4 All Grades Grade 3 or 4 Gastrointestinal disorders Nausea 37 1.6 27 1.6 Diarrhea Represents a composite of multiple related terms 21 1.2 19 2.4 Abdominal pain 20 2.8 18 3.7 Vomiting 19 0.8 15 1.6 Stomatitis 13 <0.4 4.1 0 Constipation 11 0 11 0.8 General disorders and administration site conditions Fatigue 45 5 37 8 Pyrexia 4.9 0 6 0.4 Infections and infestations 31 8 24 8 Metabolism and nutrition disorders Decreased appetite 20 <0.8 15 1.2 Musculoskeletal and connective tissue disorders Musculoskeletal pain 18 1.2 11 2 Nervous system disorder Headache 8 0 3.7 0 Vascular disorders Hypertension 11 6 2 1.2 Hemorrhage 10 1.2 3.7 0.8 Renal and urinary disorders Proteinuria 6 0.8 1.2 0 Table 6: Select Laboratory Abnormalities (≥10%) in SUNLIGHT Laboratory parameters LONSURF + Bevacizumab Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LONSURF + bevacizumab group (n=242 patients) and LONSURF group (range: 240 to 242 patients). LONSURF All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Neutrophils decreased 80 52 68 39 Hemoglobin decreased 68 5 73 11 Platelets decreased 54 4.1 29 0.8 Chemistry Aspartate aminotransferase increased 34 2.1 28 1.2 Alanine aminotransferase increased 33 3.3 23 0.4 Alkaline phosphatase increased 31 0.8 36 1.2 Sodium decreased 25 2.1 20 3.3 Potassium increased 17 0 15 0 Potassium decreased 12 0.8 12 2.5 Creatinine increased 12 0.8 15 0 Metastatic Gastric Cancer The safety of LONSURF was evaluated in TAGS, an international, randomized (2:1), double-blind, placebo-controlled trial in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who were previously treated with at least 2 prior chemotherapy regimens for advanced disease [see Clinical Studies (14.2)].

Previous treatments must have included a fluoropyrimidine, a platinum, and either a taxane or irinotecan. Patients with HER2/neu-positive tumors must have received prior HER2/neu-targeted therapy, if available. Adjuvant chemotherapy could be counted as one prior regimen in patients who had recurrence during or within 6 months of completion of the adjuvant chemotherapy.

Patients received LONSURF 35 mg/m 2 /dose (n=335) or placebo (n=168) twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle with best supportive care. In TAGS, 10% of patients received LONSURF for more than 6 months and 0.9% of patients received LONSURF for more than 1 year. The study population characteristics were: median age 63 years (24 to 89 years); 73% male; 70% White, 16% Asian, and 1% Black.

The most common adverse reactions or laboratory abnormalities (≥10% in incidence) in patients treated with LONSURF at a rate that exceeds the rate in patients receiving placebo were neutropenia, anemia, nausea, decreased appetite, thrombocytopenia, vomiting, and diarrhea. In TAGS, 13% of patients discontinued LONSURF for an adverse reaction and 11% of patients required a dose reduction.

The most common adverse reactions or laboratory abnormalities leading to dose reduction were neutropenia, anemia, febrile neutropenia, and diarrhea. Table 7 and Table 8 list the adverse reactions and laboratory abnormalities (graded using CTCAE v4.03), respectively, observed in TAGS. Table 7: Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in TAGS Adverse Reactions LONSURF (N=335) Placebo (N=168) All Grades (%) Grades 3-4 No Grade 4 definition for nausea or fatigue in NCI CTCAE, version 4.03.

(%) All Grades (%) Grades 3-4 (%) Gastrointestinal Nausea 37 3 32 3 Vomiting 25 4 20 2 Diarrhea 23 3 14 2 Metabolism and nutrition Decreased appetite 34 9 31 7 Infections Incidence reflects 46 preferred terms in the Infections and Infestations system organ class. 23 5 16 5 Table 8: Laboratory Abnormalities in TAGS Laboratory Parameter Worst Grade at least one Grade higher than baseline, with percent based on number of patients with post-baseline samples which may be <335 (LONSURF) or 168 (placebo) LONSURF Placebo All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Hematologic Neutropenia 66 38 4 0 Anemia Anemia: No Grade 4 definition in CTCAE, v4.03 63 19 38 7 Thrombocytopenia 34 6 9 0 In TAGS, pulmonary emboli occurred more frequently in LONSURF-treated patients (3.1%) compared to 1.8% for patients on placebo. Additional Clinical Experience Interstitial lung disease was reported in 15 (0.2%) patients, 3 of which were fatal, among approximately 7,000 patients exposed to LONSURF in clinical studies and clinical practice settings in Asia.

Adverse reaction frequency tables (US label) US FDA label
Table 3: Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in RECOURSE
Adverse ReactionsLONSURF (N=533)Placebo (N=265)
All Grades (%)Grades 3-4No Grade 4 definition for nausea, abdominal pain, or fatigue in National Cancer Institute Common Terminology (%)All Grades (%)Grades 3-4 (%)
General
Asthenia/fatigue527359
Pyrexia191.3140.4
Gastrointestinal
Nausea481.9241.1
Diarrhea323120.4
Vomiting282.1140.4
Abdominal pain212.4193.8
Stomatitis80.460
Metabolism and nutrition
Decreased appetite393.6294.9
InfectionsIncidence reflects 64 preferred terms in the Infections and Infestations system organ class.277164.9
Nervous system
Dysgeusia702.30
Skin and subcutaneous tissue
Alopecia701.10
Table 4: Select Laboratory Abnormalities in RECOURSE
Laboratory ParameterWorst Grade at least one grade higher than baseline, with percentages based on number of patients with post-baseline samples, which may be <533 (LONSURF) or 265 (placebo)LONSURFPlacebo
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Hematologic
AnemiaOne Grade 4 anemia adverse reaction based on clinical criteria was reported7718333
Neutropenia 67380.80
Thrombocytopenia42580.4
Table 5: Adverse Reactions (≥5%) in SUNLIGHT
Adverse ReactionsLONSURF + Bevacizumab (N=246) (%)LONSURF (N=246) (%)
All GradesGrade 3 or 4All GradesGrade 3 or 4
Gastrointestinal disorders
Nausea371.6271.6
DiarrheaRepresents a composite of multiple related terms211.2192.4
Abdominal pain202.8183.7
Vomiting190.8151.6
Stomatitis13<0.44.10
Constipation110110.8
General disorders and administration site conditions
Fatigue455378
Pyrexia4.9060.4
Infections and infestations318248
Metabolism and nutrition disorders
Decreased appetite20<0.8151.2
Musculoskeletal and connective tissue disorders
Musculoskeletal pain181.2112
Nervous system disorder
Headache803.70
Vascular disorders
Hypertension11621.2
Hemorrhage101.23.70.8
Renal and urinary disorders
Proteinuria60.81.20
Table 6: Select Laboratory Abnormalities (≥10%) in SUNLIGHT
Laboratory parametersLONSURF + BevacizumabEach test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LONSURF + bevacizumab group (n=242 patients) and LONSURF group (range: 240 to 242 patients).LONSURF
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
Hematology
Neutrophils decreased80526839
Hemoglobin decreased6857311
Platelets decreased544.1290.8
Chemistry
Aspartate aminotransferase increased342.1281.2
Alanine aminotransferase increased333.3230.4
Alkaline phosphatase increased310.8361.2
Sodium decreased252.1203.3
Potassium increased170150
Potassium decreased120.8122.5
Creatinine increased120.8150
Table 7: Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in TAGS
Adverse ReactionsLONSURF (N=335)Placebo (N=168)
All Grades (%)Grades 3-4No Grade 4 definition for nausea or fatigue in NCI CTCAE, version 4.03. (%)All Grades (%)Grades 3-4 (%)
Gastrointestinal
Nausea373323
Vomiting254202
Diarrhea233142
Metabolism and nutrition
Decreased appetite349317
InfectionsIncidence reflects 46 preferred terms in the Infections and Infestations system organ class.235165
Table 8: Laboratory Abnormalities in TAGS
Laboratory ParameterWorst Grade at least one Grade higher than baseline, with percent based on number of patients with post-baseline samples which may be <335 (LONSURF) or 168 (placebo)LONSURFPlacebo
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Hematologic
Neutropenia663840
AnemiaAnemia: No Grade 4 definition in CTCAE, v4.036319387
Thrombocytopenia34690

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on animal data and its mechanism of action [see Clinical Pharmacology (12.2)], LONSURF can cause fetal harm. LONSURF caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when given during gestation at doses resulting in exposures lower than or similar to human exposures at the recommended clinical dose (see Data).

There are no available data on LONSURF use in pregnant women. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Trifluridine/tipiracil was administered orally once daily to female rats during organogenesis at dose levels of 15, 50, and 150 mg/kg [trifluridine (FTD) equivalent].

Decreased fetal weight was observed at FTD doses ≥50 mg/kg (approximately 0.33 times the FTD exposure at the clinical dose of 35 mg/m 2 twice daily). At the FTD dose of 150 mg/kg (approximately 0.92 times the FTD exposure at the clinical dose of 35 mg/m 2 twice daily) embryolethality and structural anomalies (kinked tail, cleft palate, ectrodactyly, anasarca, alterations in great vessels, and skeletal anomalies) were observed.

Mechanism of action

12.1 Mechanism of Action LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio, 1:0.471). Inclusion of tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. Following uptake into cancer cells, trifluridine is incorporated into DNA, interferes with DNA synthesis and inhibits cell proliferation. Trifluridine/tipiracil demonstrated anti-tumor activity against KRAS wild-type and mutant human colorectal cancer xenografts in mice.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Cardiac Electrophysiology LONSURF administered to 42 patients with advanced solid tumors at the recommended dosage had no large effect (i.e. >20 ms) in the mean QTc interval when compared to placebo and no exposure-QT relationship was identified. Two of 42 patients (4.8%) had QTc >500 msec and 2.4% had a QTc increase from baseline >60 msec.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination After administration of LONSURF 35 mg/m 2 , the mean elimination half-life (t 1/2 ) of trifluridine was 1.4 hours and of tipiracil was 2.1 hours after a single dose.

The mean elimination half-life at steady state of trifluridine was 2.1 hours and of tipiracil was 2.4 hours.

Excretion After single oral administration of LONSURF (60 mg) with [ 14 C]-trifluridine, the total cumulative excretion of radioactivity was 60% of the administered dose.

The majority of recovered radioactivity was eliminated into urine (55% of the dose) as FTY and trifluridine glucuronide isomers within 24 hours and the excretion into feces and expired air was <3% for both.

After single oral administration of LONSURF (60 mg) with [ 14 C]-tipiracil hydrochloride, recovered radioactivity was 77% of the dose, which consisted of 27% urinary excretion and 50% fecal excretion.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics After twice daily dosing of LONSURF, systemic exposure (AUC) of trifluridine increased more than dose-proportionally over the dose range of 15 mg/m 2 (0.43 times the recommended dose) to 35 mg/m 2. The accumulation of trifluridine was 3-fold for AUC 0-12hr and 2-fold for C max at steady state while no accumulation was observed for tipiracil.

Administration of a single dose of LONSURF 35 mg/m 2 increased the mean AUC 0-last of trifluridine by 37-fold and C max by 22-fold with reduced variability compared to administration of a single dose of trifluridine 35 mg/m 2 alone. Absorption Following a single oral administration of LONSURF at 35 mg/m 2 in patients with cancer, the mean time to peak plasma concentration (T max) of trifluridine was around 2 hours.

Food Effect A standardized high-fat, high-calorie meal decreased trifluridine C max, tipiracil C max and AUC by approximately 40%, but did not change trifluridine AUC compared to those in a fasting state in patients with cancer following administration of a single dose of LONSURF 35 mg/m 2. Distribution Trifluridine mainly binds to human serum albumin.

The in vitro protein binding of trifluridine in human plasma is >96%, independent of drug concentration and presence of tipiracil. Plasma protein binding of tipiracil is below 8%. Elimination After administration of LONSURF 35 mg/m 2, the mean elimination half-life (t 1/2) of trifluridine was 1.4 hours and of tipiracil was 2.1 hours after a single dose.

The mean elimination half-life at steady state of trifluridine was 2.1 hours and of tipiracil was 2.4 hours. Metabolism Trifluridine and tipiracil are not metabolized by cytochrome P450 (CYP) enzymes. Trifluridine is mainly eliminated by metabolism via thymidine phosphorylase to form an inactive metabolite, 5-(trifluoromethyl) uracil (FTY).

No other major metabolites were detected in plasma or urine. Excretion After single oral administration of LONSURF (60 mg) with [14 C]-trifluridine, the total cumulative excretion of radioactivity was 60% of the administered dose. The majority of recovered radioactivity was eliminated into urine (55% of the dose) as FTY and trifluridine glucuronide isomers within 24 hours and the excretion into feces and expired air was <3% for both.

The unchanged trifluridine was <3% of administered dose recovered in the urine and feces. After single oral administration of LONSURF (60 mg) with [14 C]-tipiracil hydrochloride, recovered radioactivity was 77% of the dose, which consisted of 27% urinary excretion and 50% fecal excretion. Tipiracil was the major component and 6-HMU was the major metabolite in urine, and feces.

Specific Populations Based on the population pharmacokinetic analysis, there is no clinically relevant effect of age, sex, or race (White or Asian) on the pharmacokinetics of trifluridine or tipiracil. Patients with Renal Impairment In a dedicated renal impairment study, all patients received LONSURF 35 mg/m 2 twice daily except for patients with severe renal impairment who received 20 mg/m 2 twice daily.

Mild renal impairment (CLcr of 60 to 89 mL/min as determined by the Cockcroft-Gault formula) had no clinically important effect on steady-state AUC 0-last of trifluridine and tipiracil. Moderate renal impairment (CLcr of 30 to 59 mL/min) increased steady-state AUC 0-last of trifluridine by 56% and tipiracil by 139% compared to normal renal function (CLcr ≥ 90 mL/min).

Severe renal impairment (CLcr of 15 to 29 mL/min) increased the dose-normalized steady-state AUC 0-last of trifluridine by 140% and tipiracil by 614% compared to normal renal function. The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with end stage renal disease. Patients with Hepatic Impairment No clinically important differences in the mean exposures of trifluridine and tipiracil were observed between patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN or total bilirubin <1 to 1.5 times ULN and any AST) to moderate hepatic impairment (total bilirubin >1.5 to 3 times ULN and any AST) and patients with normal hepatic function (total bilirubin and AST ≤ ULN); however, 5 of 6 patients with moderate hepatic impairment experienced Grade 3 or 4 increased bilirubin levels.

The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with severe hepatic impairment [see Dosage Modifications (2.2), Use in Specific Populations (8.6)]. Drug Interaction Studies In vitro studies indicated that trifluridine, tipiracil, and FTY did not inhibit the CYP enzymes and had no inductive effect on CYP1A2, CYP2B6, or CYP3A4/5.

In vitro studies indicated that trifluridine was not an inhibitor of or substrate for human uptake and efflux transporters.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. LONSURF · Taiho Pharmaceutical Co., Ltd. [US FDA-approved label, version 15, November 5, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5beed22-d71d-4c0d-8dca-2c7317d65d85
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .